Investors in WuXi Biologics Reap Impressive 247% Return over Last 5 Years
December 27, 2022
Trending News ☀️
Wuxi Biologics Stock Fair Value – WUXI ($SEHK:02269): WuXi Biologics is a leading, fully integrated global open-access biologics technology platform company. It also offers a wide range of services, including R&D, CMC, process development and manufacturing, laboratory testing, and clinical trial management services. Investors in WuXi Biologics have seen an impressive 247% return on their investment over the past five years. The company has seen strong revenue growth over the past five years as it continues to expand its business and enter new markets. It has also been working to increase its manufacturing capabilities, improve its customer service and develop new technologies to support its growth. This has helped to drive the company’s stock price higher.
In addition, WuXi Biologics has been actively investing in research and development to further its capabilities. This has allowed it to stay ahead of its competitors and provide innovative solutions to its customers. These investments have helped to fuel the company’s growth and increase investor confidence in the stock. Overall, investors in WuXi Biologics have been well rewarded for their investment over the past five years. The company’s strong performance, innovative solutions, and commitment to research and development have all contributed to its impressive returns. As WuXi Biologics continues to strengthen its position in the biopharmaceuticals sector, investors can expect these impressive returns to continue in the future.
Share Price
At the time of writing, most of the news about the company is positive. On Wednesday, WUXI BIOLOGICS stock opened at HK$50.3 and closed at HK$51.2, up by 2.5% from its last closing price of 50.0. This is indicative of the strong performance of WuXi Biologics in recent years. The company has positioned itself as one of the leading global open-access biologics technology platforms, providing integrated and complete solutions to enable its partners to accelerate the development and manufacturing of biologics products. This has allowed WuXi Biologics to become a key player in the biologics industry, and investors have been quick to recognize this potential. In addition to the positive news about WuXi Biologics, the company has also recently announced that it is expanding its operations in Europe.
This will further enhance their reach and expand their customer base. Furthermore, the company is investing heavily in research and development as well as marketing initiatives to strengthen their position as a global leader in the biologics industry. The strong performance of WuXi Biologics has been driven by a combination of factors, including a healthy market for biologics, an experienced management team, and a solid track record of delivering results. Investors can expect this trend to continue if WuXi Biologics continues to execute its plans and meet its goals. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Wuxi Biologics. More…
| Total Revenues | Net Income | Net Margin |
| 13.09k | 4.08k | 33.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Wuxi Biologics. More…
| Operations | Investing | Financing |
| 4.09k | -4.22k | -3.23k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Wuxi Biologics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 47.47k | 11.99k | 8.08 |
Key Ratios Snapshot
Some of the financial key ratios for Wuxi Biologics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 61.9% | 68.2% | 37.5% |
| FCF Margin | ROE | ROA |
| -8.0% | 9.2% | 6.5% |
VI Analysis – Wuxi Biologics Stock Fair Value Calculator
WUXI BIOLOGICS, a company listed on the Hong Kong Stock Exchange, is a biopharmaceutical company that develops, manufactures and commercializes biologics products. With the help of VI app, it is easy to analyze the fundamentals of the company, which reflect its long term potential. According to the VI Line analysis, the intrinsic value of WUXI BIOLOGICS share is around HK$115.9. It is evident that WUXI BIOLOGICS stock is currently undervalued, since it is being traded at HK$51.2 per share, which is 56% lower than its intrinsic value. This presents a great opportunity for investors to benefit from the great potential of this company. It is important to note that there are other factors that can affect the stock price of WUXI BIOLOGICS, such as market conditions, industry trends and macroeconomic developments. Therefore, investors should take into consideration all these factors before investing in the stock. Moreover, they should also diversify their investments across different asset classes to reduce the risk of losses. More…
VI Peers
In the global market for biologics, WuXi Biologics (Cayman) Inc faces stiff competition from Innovent Biologics Inc, Biocon Ltd, and Avid Bioservices Inc. All four companies are striving to develop and commercialize innovative therapies to treat a variety of serious and life-threatening diseases. While WuXi Biologics has carved out a significant market share, its competitors are also major players in this growing industry.
– Innovent Biologics Inc ($SEHK:01801)
Innovent Biologics Inc is a Chinese biopharmaceutical company with a focus on developing immunotherapies for the treatment of cancer. The company has a market cap of 41.68B as of 2022 and a Return on Equity of -18.61%. The company’s products include the anti-PD-1 antibody Tyvyt and the anti-VEGF antibody Sintilimab, both of which are approved in China for the treatment of certain types of cancer.
– Biocon Ltd ($BSE:532523)
Biocon Ltd is an Indian biotechnology company that is involved in the development, manufacture, and marketing of pharmaceuticals and biopharmaceuticals. The company has a market cap of 323.56B as of 2022 and a Return on Equity of 8.02%. Biocon was founded in 1978 by Kiran Mazumdar-Shaw and is based in Bangalore, India. The company’s products include insulin, biosimilars, monoclonal antibodies, and enzymes. Biocon has a strong presence in India and also has operations in the United States, Europe, and Asia.
– Avid Bioservices Inc ($NASDAQ:CDMO)
Avid Bioservices is a contract development and manufacturing organization (CDMO) that provides development and cGMP manufacturing services for biopharmaceutical companies. The company has a market cap of $994.68M as of 2022 and a ROE of 3.93%. Avid Bioservices offers a range of services, including cell line development, process development, cGMP manufacturing, and analytical testing. The company’s clients include both large and small biopharmaceutical companies.
Summary
The news surrounding the company has been mostly positive, with many anticipating continued success for the company moving forward. With a focus on biologics, WuXi Biologics is well positioned to capitalize on the rapidly growing biotechnology industry, providing investors with a great opportunity to benefit from the company’s growth. Despite the potential risks associated with investing in any company, WuXi Biologics remains a strong investment for those willing to take on the risk.
